DarioHealth Wins Key Contract Ensuring Its Platform to be Utilized in Clinical Study

NEW YORK and CAESAREA, Israel, Feb. 8, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing diabetes. The pharmaceutical company is seeking FDA clearance for this drug and has selected DarioHealth to run and track the blood glucose readings of participants in the clinical study.

DarioHealth has shown tremendous capabilities in demonstrating its value to consumers, which is now being recognized by securing this clinical study contract and by other verticals in the B2B diabetes space. DarioHealth's B2B platform aims to increase user engagement during the course of the clinical study and will leverage key learnings from the Company's direct-to-consumer success, including allowing the participants to log their BGM readings in real-time in the Dario logbook and utilize features like reminders and statistics.

Erez Raphael, Chairman and CEO of DarioHealth, commented, "We are thrilled to have been chosen for this important clinical study. Our Dario all-in-one platform was selected because of its ability to help patients in all aspects of managing diabetes with stronger user engagement, and real-time access to results. This move into clinical studies and clinician practices shows the adoption of our products and solutions going beyond the scope of just the consumer.

"We believe that this initial adoption of DarioHealth's BGM platform by the clinical side of the industry will broaden our revenue stream beyond the device and strip business. By doing so, we will be able to make key learnings as we continue to develop new products and services to improve the greater healthcare ecosystem. Our vision for the future includes more solutions that pick up where the Dario™ Blood Glucose Monitoring System ends and I believe this all begins today, as we assist a pharmaceutical company in their clinical study."

About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease treatment, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it describes its vision for the future, developing new products and services, the benefits of the adoption of its products into clinical studies and the related anticipated broadening of the Company's revenue stream. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:Shmuel Herschberg, Marketing Director, shmuel@mydario.com, +1-914-775-5548

DarioHealth Public Relations Contact:Terese Kelly, Rosica PR, terese@rosica.com, +1-201-843-5600

DarioHealth Investor Relations Contact: Westwicke Partners, Dario@Westwicke.com, +1-443-213-0500

View original content:http://www.prnewswire.com/news-releases/dariohealth-wins-key-contract-ensuring-its-platform-to-be-utilized-in-clinical-study-300595737.html

SOURCE DarioHealth Corp.